

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/04, 1/06, 1/18	A1	(11) International Publication Number: WO 99/23244
		(43) International Publication Date: 14 May 1999 (14.05.99)
<p>(21) International Application Number: PCT/US98/23384</p> <p>(22) International Filing Date: 3 November 1998 (03.11.98)</p> <p>(30) Priority Data: 60/064,057 3 November 1997 (03.11.97) US</p> <p>(71) Applicant: SMALL MOLECULE THERAPEUTICS, INC. [US/US]; Suite 116, 11 Deer Park Drive, Monmouth Junction, NJ 08852 (US).</p> <p>(72) Inventors: MENZEL, Rolf; 7 Shelley Lane, Yardley, PA 19067 (US). ELSEMORE, David, A.; 1223 Town Court North, Lawrenceville, NJ 08648 (US).</p> <p>(74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
(54) Title: METHODS AND COMPOSITIONS FOR MODULATION OF BACTERIAL TOPOISOMERASE ENZYMES		
<p>(57) Abstract</p> <p>The present invention relates to methods and compositions for the modulation of bacterial topoisomerase enzymes within bacterial cells. More specifically, the present invention relates to bacterial assays wherein the levels of bacterial topoisomerase enzymes or the levels of target sites within the enzymes are varied within bacterial test strains in order to screen for compounds that target, i.e., interact with the topoisomerase enzymes, causing DNA damage and hence bacterial growth inhibition and/or cell death. The present methods and compositions are useful for the identification and characterization of novel therapeutic antibacterial compounds.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**METHODS AND COMPOSITIONS FOR
MODULATION OF BACTERIAL TOPOISOMERASE ENZYMES**

1. INTRODUCTION

The present invention relates to methods and compositions for the modulation of bacterial topoisomerase enzymes within bacterial cells. More specifically, the present invention relates to bacterial assays wherein the levels of bacterial topoisomerase enzymes or the levels of target sites within the enzymes are varied within bacterial test strains in order to screen for compounds that target, i.e., interact with the topoisomerase enzymes, thereby causing DNA damage and hence, bacterial growth inhibition and/or cell death. The present methods and compositions are useful for the identification and characterization of novel therapeutic antibacterial compounds.

2. BACKGROUND OF THE INVENTION

DNA topoisomerases are enzymes that affect the topology or structure of DNA. More specifically, these enzymes have the ability to introduce supercoils into DNA molecules or relax the DNA molecules; they can catenate or decatenate circular DNA or they can knot or unknot DNA (Schmid et al., 1993, BioEssays 15 (No. 7): 445-449). The DNA topoisomerases act by catalyzing the breakage and rejoining of the DNA phosphodiester backbone (Wang, 1985, Annu. Rev. Biochem. 54: 665-697; Vosberg, 1985, Curr. Top. Microbiol. Immunol. 114: 19-102). These reactions, together with an intervening strand passage event, allow the topoisomerases to alter DNA topology. In fact, correct topoisomerase function is necessary for such basic cellular processes as DNA replication and transcription.

More specifically, the DNA topoisomerases are classified into two types. Type I topoisomerases act by causing a transient break in one strand of the double-stranded DNA and passing one strand of DNA through another, thereby allowing for the relaxation of supercoiled DNA and decatenation of interlocked circular DNA molecules (Schmid et al., *supra*).

In contrast, the Type II DNA topoisomerases alter DNA topology by causing transient breaks in both strands of a double-stranded DNA, allowing the passage of one double-stranded DNA molecule through another. Like the Type I DNA topoisomerases, the Type II topoisomerases also allow the relaxation and decatenation of DNA; however, one bacterial Type II topoisomerase, DNA gyrase, also has the ability to introduce negative supercoils into relaxed DNA. In either type of topoisomerase, after the strand passage event, the final step of the reaction is the rejoining or ligation of the DNA break(s).

Analysis of the mechanism of action of the DNA topoisomerases on the molecular level indicates that these enzymes introduce breaks in the DNA molecule by forming a covalent phosphotyrosine bond between a specific tyrosine amino acid residue present on the topoisomerase and the phosphodiester backbone of the DNA. Thus, an intermediate in the catalytic reaction of these enzymes is a covalently-linked enzyme-DNA complex, sometimes termed the cleavable complex (see, e.g., Liu, 1990, DNA Topology and Its Biological Effects, Cozzarelli and Wang (eds.), Chapter 14, pp. 371-372, Cold Spring Harbor Press). It is this cleavable complex that forms the molecular target for therapeutic compounds that can interact with this intermediate, stabilizing it, i.e., trapping it, such that the subsequent DNA strand ligation step of the reaction cannot be completed.

In bacteria, two Type I topoisomerase enzymes have been described: Topoisomerase I (Topo I) and Topoisomerase III (Topo III). Topo I, encoded by the *topA* gene, is responsible for the major DNA relaxing activity of the cell, and catalyzes the relaxation of DNA through the sequential breakage-strand-passage-religation cycle common to all topoisomerase enzymes. Topo III represents a minor activity encoded by the *topB* gene, is less well-characterized and its role in vivo is less clear, although the molecule appears to possess decatenation activity (Schmid et al., supra at p. 447). Bacteria also have two Type II topoisomerases: DNA

gyrase (Topo II) and Topoisomerase IV (Topo IV). As noted supra, DNA gyrase catalyzes negative supercoiling in DNA; Topo IV has been found to catalyze decatenation of interlinked DNA, e.g., subsequent to DNA replication, as well as play a role in DNA relaxation. Although Topo IV shares extensive homology with DNA gyrase (40-50% amino acid identity), it differs from DNA gyrase in the activities it can catalyze. For example, Topo IV cannot couple the hydrolysis of ATP to the process of DNA supercoiling as gyrase can, but it is able to relax DNA in an ATP-stimulated fashion.

In contrast to the bacteria, eukaryotes, such as yeast and humans, possess a single Type I DNA topoisomerase (see, e.g., Wang, J.C., 1987, J. Biochem. Biophys. Acta. 909: 1-9). Furthermore, this eukaryotic topoisomerase is distinct from bacterial Topo I in both structure and function. For example, the bacterial and eukaryotic Topo I enzymes share no amino acid sequence homology. In addition, the eukaryotic enzyme shows a preference for binding double-stranded DNA and catalyzes its reaction by forming a covalent 3'-phosphodiester intermediate. In contrast, the bacterial Topo I enzyme shows a preference for binding at the junction of double and single-stranded regions and catalyzes its reaction by forming a 5'-phosphodiester intermediate (see, e.g., Taylor and Menzel, 1995, Gene 167: 69-74). Finally, it is of interest to note that, while the human Topo I enzyme is the target of the antitumor drug camptothecin (CPT), the bacterial enzyme is resistant to that drug. Eukaryotes also possess a Type II DNA topoisomerase that demonstrates some structural and evolutionary relationship to bacterial gyrase (Wang, 1994, Advances in Pharmacology, Volume 29A, Liu (ed.), Academic Press).

While the bacterial Type I topoisomerase, Topo III, appears to be non-essential to the viability of the cell (Hiasa, et al., 1994, J. Biol. Chem. 269: 2093-2099), Topo I is essential in an otherwise normal bacterial cell. Nevertheless, the *topA* gene may be deleted or otherwise

rendered inactive, provided that certain second site compensatory mutations are present in the *topA* strains, leading some to question the essential nature of the bacterial Topo I enzyme (Pruss et al., 1982, Cell 31: 35-42; 5 DiNardo et al., 1982, Cell 31: 43-51).

Second site mutations that compensate for the loss of *topA* do so by altering the activity or levels of other topoisomerase enzymes in the mutant host cell. For example, mutations that compensate for the loss of bacterial Topo I 10 have been mapped to the two genes (*gyrA* and *gyrB*) that encode the bacterial Type II DNA topoisomerase, DNA gyrase. These mutations have been shown to reduce the levels and activity of DNA gyrase, suggesting a balance between the competing activities of topoisomerases that introduce DNA supercoils 15 (i.e., DNA gyrase) and those that remove or relax DNA supercoils (e.g., Topo I).

Still other mutations that compensate for the loss of *topA* in a *topA* mutant have been mapped to a region of the chromosome encoding the *parC* and *parE* genes which encode the 20 subunits of the bacterial Type II topoisomerase, Topo IV. The majority of these compensatory mutations are duplications of the *parC,E* region of the chromosome. Such duplications are believed to increase the copy number, and hence the level, of Topo IV within the bacterial cell. It has also 25 been shown that extra copies of Topo IV-encoding sequences on a plasmid are able to compensate for a loss of *topA*.

As noted supra, compounds that can trap the cleavable complex intermediate formed during the catalytic reaction of the DNA topoisomerases represent important drugs. For 30 example, compounds that trap the covalent intermediates involved in the catalytic reactions of the eukaryotic DNA topoisomerases have been shown to represent important anticancer drugs; e.g., the anticancer drugs Etoposide and Adriamycin trap the covalent intermediate of human Type II 35 topoisomerases. As noted supra, camptothecins, another important class of anticancer drug, trap the DNA intermediate of human Type I topoisomerase but do not affect the bacterial

Type I topoisomerases (Drlica, K. et al., Biochem. 27: 2253-2259). In the area of antibacterial drugs, a major class of antibiotics, the quinolones, have been shown to trap the cleavable complex of the bacterial DNA gyrase enzyme. The
5 quinolones have also been shown to trap the intermediate formed during the catalytic reaction of Topo IV (Drlica et al., September 1997, Microbiology and Molecular Biology Reviews, 61 (No. 3): 377-392).

Model systems for the study of eukaryotic Type I DNA
10 topoisomerases have been reported (Nitiss, J. et al., 1988, Proc. Natl. Acad. Sci. USA 85: 7501-7505; M.-A., Bjornsti et al., 1989, Cancer Research 49: 6318-6323; Menzel, R. et al., U.S. Patent No. 5,656,495). To date, however, no model
15 systems exist for the systematic identification of compounds which target the bacterial DNA topoisomerases. Furthermore, no bacterial assays have been reported which utilize varying levels of bacterial DNA topoisomerase targets within
bacterial cells to screen for drugs that interact with those enzymes in the identification of antibacterial compounds, as
20 disclosed herein. The methods and compositions of this invention can lead to the identification and use of important new antibacterial compounds.

3. SUMMARY OF THE INVENTION

25 The present invention relates to methods and compositions for the identification of new antibacterial compounds. More specifically, the present invention relates to bacterial assays or screens, wherein the levels of bacterial DNA topoisomerases or target sites within the
30 topoisomerases are varied in bacterial test strains in order to identify compounds that target, i.e., interact with topoisomerase enzymes within the bacterial cell, thereby causing DNA damage which leads to cell growth inhibition and/or cell death. The methods and compositions of the
35 invention therefore identify potent antibacterial compounds that act through their effects on bacterial DNA topoisomerases.

According to this invention, screens are performed for identifying test compounds that arrest the reaction catalyzed by the bacterial DNA topoisomerases. Such compounds are referred to as "poisons" and, as herein defined, these 5 poisons interact with the DNA topoisomerase cleavable complex intermediate, trapping the intermediate and thus blocking the DNA rejoining step of the topoisomerase catalytic reaction. As such, these poisons possess an antibacterial therapeutic effect, not through inhibition of the catalytic activity of 10 the enzyme per se, but rather via their ability to cause lethal DNA damage (see, e.g., Liu, supra at pp. 371-372; Wang, supra at p. 9). For example, one class of poisons acts to trap the bacterial Topo I cleavage complex intermediate. Another class of poisons acts to trap the bacterial Type II 15 DNA topoisomerases, e.g., DNA gyrase and Topo IV.

The assays or screens of this invention comprise contacting a test compound to a bacterial test strain A and a bacterial test strain B wherein the test strains are isogenic, except that the two strains exhibit a differential 20 level of test compound topoisomerase "targets", that is, elements or sites within the topoisomerase enzyme that allow interaction with the test compound or poison. According to this invention, a differential level of such targets can be achieved by decreasing or increasing the level of the 25 topoisomerase enzyme itself (e.g., via deletion or duplication mutations) or by decreasing or increasing the number of functional sites within the enzyme that allow interaction with the test compound or poison.

Since it is the presence of the topoisomerase target 30 that enables a topoisomerase poison to exert its antibacterial effect, i.e., DNA damage (due to the interaction between the poison and the target intermediate), elevated levels of the topoisomerase target in one test strain relative to another leads to a differential, e.g., 35 increased sensitivity to the test compound that can be measured as a function of DNA damage. Therefore, if, upon exposure of test strains A and B as defined above to a test

compound, a differential sensitivity is detected between the two strains, that test compound is identified as a DNA topoisomerase poison. As used herein, "differential sensitivity" refers to a differential amount or measure of DNA damage to the bacterial cells, which can be detected by assays of cell death and/or growth inhibition of the cells (indirect measures of DNA damage) or by standard DNA damage or DNA cleavage assays (direct measures). According to a preferred embodiment, a differential sensitivity between the test strains is first detected using an indirect measure of DNA damage such as a growth inhibition assay and the DNA damage ability/activity of the test compound/poison is further confirmed by standard DNA damage or cleavage assays using known substrates (see, e.g., Sections 6.4 and 6.5, infra).

The assays and compositions of this invention are useful for the identification of either bacterial Topo I poisons or bacterial Type II topoisomerase poisons. Thus, according to one embodiment of the present invention, a screen for identifying Topo I poisons comprises contacting a test compound to two bacterial test strains that are isogenic except that one of the strains has a reduced level of Topo I enzyme targets relative to the other. The differential inhibition of growth and/or cell death exhibited by the two strains relative to each other is measured. Alternatively or additionally, assays and biochemical tests can be performed to determine the differential DNA damage exhibited by the two test strains. A test compound that causes an increased amount of DNA damage, growth inhibition and/or killing of the strain that has the elevated level of Topo I targets relative to the other strain indicates that the test compound works in concert with Topo I to poison the cell; that test compound is therefore identified as an antibacterial Topo I poison.

According to one embodiment of this invention, bacterial test strains A and B are isogenic strains that differ only in that one strain contains a *topA* mutation which decreases the level of Topo I or Topo I targets within the bacterial cell.

According to a preferred embodiment, the *topA* mutation is a deletion mutation. A test compound is contacted to the test strains and the differential sensitivity of the strains relative to each other is measured. A test compound that
5 demonstrates a differential, in this case, an increased DNA damage, growth inhibition and/or killing of the wild type bacterial strain relative to the *topA* mutant strain is identified as a Topo I poison.

In another embodiment, a single bacterial test strain
10 containing a *topA* mutation that results in a loss or decreased level of Topo I targets additionally contains a second DNA sequence encoding a functional *topA* gene. For example, the strain can contain a plasmid or other extrachromosomal DNA sequence having a functional *topA* gene
15 under the regulatory control of an inducible promoter for the regulated production of Topo I. Alternatively, a functional *topA* gene operably linked to an inducible promoter may be inserted directly into the bacterial DNA. According to this embodiment, the strain is studied under two different
20 conditions: in one, the strain is induced to express Topo I, while in the other, it is not. As with the Topo I poison screen discussed supra, a test compound that causes a differential DNA damage, growth inhibition and/or killing of the bacterial strain induced to produce Topo I relative to
25 the non-induced *topA* mutant strain is identified as a Topo I poison. According to a preferred embodiment, the *topA* mutation is a deletion mutation.

According to another embodiment of the present invention, a screen for identifying bacterial Type II DNA
30 topoisomerase poisons comprises contacting a test compound to two bacterial test strains that are isogenic except for the fact that one of the strains has a reduced level of bacterial Type II DNA gyrase targets and the second strain has an increased level of Type II Topo IV targets. According to a
35 preferred embodiment, the levels of the enzymes themselves are varied such that one of the strains has a reduced level of the bacterial gyrase enzyme and the other strain has an

increased level of the Topo IV enzyme. The strain with reduced levels of the gyrase enzyme will possess a decreased number of targets for a Type II-specific poison whereas the strain with increased levels of Topo IV will possess an increased level of targets for a Type II-specific poison. A differential, in this case, increased DNA damage, growth inhibition and/or cell death exhibited by the strain with the elevated level of Type II DNA topoisomerase relative to the strain having reduced levels of Type II targets indicates that the test compound works in concert with the Type II topoisomerase enzymes to poison the cell. Such a test compound is identified according to the assays of this invention as an antibacterial Type II DNA topoisomerase poison.

According to one embodiment of this invention, the isogenic test strains are *topA*⁺ and according to another embodiment, they are *topA*⁻. In an alternative embodiment, a bacterial strain with reduced gyrase levels and a bacterial strain with increased Topo IV levels are compared respectively, i.e., separately, to isogenic strains that are wild type for each mutation in order to identify Type II poisons that are specific for the gyrase or Topo IV enzymes.

As noted supra, in *topA*⁻ mutants, the *topA* mutations must be compensated for by second site mutations in order for the bacterial cells to maintain their viability. All *topA*⁻ strains used in the embodiments of this invention therefore further comprise mutations which compensate for *topA* defects, including but not limited to mutations in the *gyrA* and/or *gyrB* genes or in the *parC* and/or *parE* genes.

30

4. BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-1C. FIG. A) A schematic diagram showing that various bacterial DNA topoisomerases act in concert to maintain a balance in the level of DNA supercoiling. FIG. B) Reducing DNA gyrase activity, and thereby restoring the balance by decreasing DNA supercoiling activity, can compensate for the loss of *topA*. FIG. C) Increasing Topo IV

activity, and thereby restoring the balance by increasing DNA relaxing activity, will also act to compensate for the loss of *topA*.

FIG. 2. Series of genetic events involved in the construction of isogenic strains for the identification of bacterial Topo I and Type II topoisomerase poisons.

FIGS. 3A-3B. Schematic diagrams of the plasmids used for the inducible expression of *E.coli* topoisomerase I (FIG. 3A) and *S. aureus* topoisomerase I (FIG. 3B).

FIGS. 4A and 4B. Schematic depiction of a Topo I *topA* deletion screen (FIG. 4A) and a Topo I inducible expression screen (FIG. 4B).

FIG. 5. Schematic depiction of a Type II topoisomerase poison screen comparing strain A containing reduced levels of DNA gyrase with strain B containing elevated levels of Topo IV.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to bacterial assays or screens that allow the identification of compounds or "poisons" that possess antibacterial activity through their effects on the bacterial DNA topoisomerases.

The term "poison" as used herein refers to compounds that interact with the cleavable complex intermediate formed during the catalytic reaction of the bacterial DNA topoisomerases. Such poisons trap the intermediate and block the DNA rejoining step of the catalytic reaction. These types of compounds thus exert their antibacterial effect by damaging the DNA of the bacterial cell (see, e.g., Liu, supra at pp. 371-372; Wang, supra at p. 9). As used herein, the term "Topo I poison" refers to those compounds that act by trapping the cleavable complex intermediate of bacterial Type I Topoisomerase I, also referred to herein as Topo I. The term "Type II poison" refers to those compounds that act by trapping the cleavable complex intermediate of bacterial Type II topoisomerases, such as DNA gyrase or Topo IV.

In order to identify and isolate the antibacterial DNA topoisomerase poisons described above, the present invention provides bacterial assays wherein the levels of bacterial DNA topoisomerase enzyme targets are varied in bacterial test strains, thus providing differential levels of targets for topoisomerase poisons. According to this invention, the bacterial test strains are isogenic, except that the strains possess differential levels of DNA topoisomerase targets. According to a preferred embodiment, the strains possess differential levels of DNA topoisomerase enzymes. The test strains are then exposed to a test compound and the differential sensitivity of the strains to the compound is assessed. As noted supra, a differential sensitivity exhibited by the bacterial cells according to this invention is a differential amount or degree of DNA damage, which can be detected by cell death or growth inhibition assays such as growth sensitivity assays which can be performed in liquid culture media employing microtiter plates or growth sensitivity assays in agar such as that described in Section 6.2 infra, wherein differential sensitivity to the test compound is measured by assessing zones of growth inhibition.

Alternatively, the DNA damage inflicted on the bacterial cells by these poisons may be identified by direct DNA damage or DNA cleavage assays or techniques known in the art. For example, an alkali elution profile of cleaved DNA is a well-known method for demonstrating DNA damage (see, e.g., Markovitz et al., 1987, Cancer Research 47: 2050-2055). Alternatively, a DNA damage inducible promoter assay can be used, wherein the level of DNA damage is assessed by measuring the level of a reporter gene whose expression is driven by a regulatory sequence induced by the DNA damage. Such DNA damage-inducible regulatory sequences can be introduced into the test strains prior to the screen and include, but are not limited to, promoters induced as part of the bacterial SOS response. For example, one such regulatory sequence is the *sulA* promoter sequence, the sequence of which is well known to those of skill in the art (see, e.g., Mamber

et al., 1990, Antimicrobial Agents and Chemotherapy 34: 1237-1243 and Kenyon et al., 1982, J. Mol. Biol. 160: 445-457). Thus, the DNA damage caused by a potential topoisomerase poison can be detected, for example, by measuring the level of a reporter gene product whose expression is driven by the *sulA* promoter sequence.

The reporter sequence can be any detectable gene product. Reporter sequences can include, but are not limited to, LacZ (betagalactosidase) and CAT (chloramphenicol acetyltransferase) gene products. Methods for detection using reporter sequences including, but not limited to those described above, are well known to those of skill in the art. An *E.coli* strain, referred to herein for exemplary purposes only, which contains a *sulA-lac* construct as a DNA inducible reporter construct is *E.coli* strain GR4413 (Huisman, O. et al., 1981, Nature 290:797-799). See, e.g., Taylor and Menzel, 1995, Gene 167: 69-74 for an example of the use of a *sulA-lac* regulatory-reporter construct in a DNA damage assay.

According to a preferred embodiment of the invention, the differential DNA damage exhibited by the test strains due to a test compound is detected using a growth inhibition assay, preferably in agar (see Section 6.2, *infra*). This allows for a more rapid and efficient screening of many compounds in as short a time as possible. The DNA damage activity of a test compound identified as a poison according to this screen can then be further confirmed by various DNA damage or cleavage assays as exemplified *infra* in Sections 6.4 and 6.5. More specifically, the DNA damage assay of Section 6.4 can be used to demonstrate actual DNA cleavage that is dependent on the presence of both the specific purified DNA topoisomerase enzyme and the poison compound in question (see, e.g., Anderson et al., 1994, in Topoisomerase Biochemistry and Molecular Biology, Liu (ed.), pp. 83-101).

Since, according to this invention, the topoisomerase poison requires the presence of the topoisomerase target for its antibacterial effect, elevated levels of the target in one test strain relative to another leads to a differential,

and in such a case, increased sensitivity to a test compound that acts as a topoisomerase poison. Conversely, reduced levels of the topoisomerase target in one test strain, e.g., in a *topA* deletion mutant relative to an otherwise isogenic wild type strain, leads to a differential sensitivity and in that case, a decreased sensitivity on the part of the mutant strain to a test compound that is a topoisomerase poison.

It is of interest to note that the drug screening approach of this invention is therefore unlike the more traditional drug screening approaches, where the desired cytotoxic effect of a drug is due to a simple inhibition of a target gene product and therefore reduced target levels result in a greater sensitivity to the drug. As indicated, in the present invention, the drug or antibacterial compound requires the target gene product in order to have its cytotoxic effect and therefore reduced target levels result in a greater resistance to the antibacterial compound, while elevated target levels result in a greater sensitivity to the drug.

Test compounds that can be screened for antibacterial activity using the methods and compositions of this invention include, but are not limited to, compounds obtained from any commercial source, including Aldrich (1001 West St. Paul Ave., Milwaukee, WI 53233), Sigma Chemical (P.O. Box 14508, St. Louis, MO 63178), Fluka Chemie AG (Industriestrasse 25, CH-9471 Buchs, Switzerland (Fluka Chemical Corp. 980 South 2nd Street, Ronkonkoma, NY 11779)), Eastman Chemical Company, Fine Chemicals (P.O. Box 431, Kingsport, TN 37662), Boehringer Mannheim GmbH (Sandhofer Strasse 116, D-68298 Mannheim), Takasago (4 Volvo Drive, Rockleigh, NJ 07647), SST Corporation (635 Brighton Road, Clifton, NJ 07012), Ferro (111 West Irene Road, Zachary, LA 70791), Riedel-deHaen Aktiengesellschaft (P.O. Box D-30918, Seelze, Germany), PPG Industries Inc., Fine Chemicals (One PPG Place, 34th Floor, Pittsburgh, PA 15272). Further any kind of natural products may be screened using the methods of the invention, including microbial, fungal or plant extracts.

Furthermore, diversity libraries of test compounds, including small molecule test compounds, may be commercially obtained from Specs and BioSpecs B.V. (Rijswijk, The Netherlands), Chembridge Corporation (San Diego, CA),
5 Contract Service Company (Dolgoprudny, Moscow Region, Russia), Comgenex USA Inc. (Princeton, NJ), Maybridge Chemicals Ltd. (Cornwall PL34 OHW, United Kingdom), and Asinex (Moscow, Russia). Combinatorial libraries of test compounds, including small molecule test compounds, can be
10 may be generated as disclosed in Eichler & Houghten, 1995, Mol. Med. Today 1:174-180; Dolle, 1997, Mol. Divers. 2:223-236; Lam, 1997, Anticancer Drug Des. 12:145-167. These references are incorporated hereby by reference in their entirety.

15 The present invention is divided into the following sections solely for the purpose of description: (a) methods and compositions for screening for bacterial Topo I poisons; and (b) methods and compositions for screening for bacterial Type II topoisomerase poisons. It is to be noted that for
20 each of the methods described below, according to one embodiment of the invention, the bacterial test cells utilized are those that are particularly permeable, thereby facilitating entry of the test compounds into the cells. For example, such cells can include, but are not limited to,
25 cells with *imp* mutations. Among the *imp* mutations that can be utilized in this regard is the *imp* 4213 mutation (Sampson, B.A. et al., 1989, Genetics 122:491-501). Furthermore, bacterial strains that can be used in the screens of this invention include, but are not limited to, *E. coli*,
30 *Salmonella typhimurium*, *S. aureus*, *S. fecalis*, *P. aeruginosa*, *M. tuberculosis*, and *H. pylori*.

5.1. METHODS AND COMPOSITIONS FOR SCREENING FOR BACTERIAL TOPO I POISONS

35 According to the present invention, bacterial screens are provided for identifying bacterial Topo I topoisomerase poisons. These bacterial assays comprise contacting a test

c mpound to two bacterial test strains that are isogenic except that one of the strains has a reduced level of bacterial Topo I enzyme targets relative to the other. After an appropriate exposure to the test compound, the
5 differential sensitivity of the test strains to the test compound is determined. A test compound that causes an increased amount of DNA damage, growth inhibition and/or killing of the strain that has the elevated level of Topo I targets relative to the other strain is identified as an
10 antibacterial Topo I poison.

According to one embodiment of this invention, isogenic bacterial test strains A and B differ only in that one strain is *topA*. As used herein, the term "*topA*" refers to any *topA* mutation that decreases the level of Topo I or Topo I targets
15 within the cell, including but not limited to a deletion of the *topA* gene. According to a further preferred embodiment of this invention, isogenic bacterial test strains A and B differ only in that one strain contains a *topA* deletion mutation or other genetic alteration of the *topA* gene and
20 thereby exhibits greatly reduced levels of the bacterial Topo I enzyme or is missing the enzyme entirely. See Figure 2 for an illustration of the genetic events involved in the construction of a bacterial strain containing a *topA* deletion. As noted supra, in order to retain their viability
25 for these screens, *topA* mutant strains must possess a second site mutation, such as in the *gyrA* and/or *gyrB* genes, or in the *parC* and/or *parE* genes, in which the second site mutation compensates for the loss of the relaxing activity of the Topo I enzyme. In the case of mutations in the *gyrA* or *gyrB*
30 genes, such mutations reduce the endogenous supercoiling activity of the gyrase enzyme and thus compensate for the loss of the relaxing activity normally provided by the Topo I enzyme. In the case where the second site mutation involves duplications in the *parC* and/or *parE* genes, such mutations
35 provide increased relaxing activities to the cell, thus compensating for the relaxing activity lost via the *topA* mutation (see FIG. 1).

Since the strains used in this embodiment of the invention must be isogenic except for the absence or presence of the *topA* mutation, the non-*topA* test strain must also contain the same compensatory second site mutations contained
5 in the *topA* mutant strain. Strains that can be used according to this invention include *E.coli* RFM475(*gyrB*^u *topA*⁻) (Drolet, 1995, Proc. Natl. Acad. Sci. 92: 3526-3530) and its companion strain RFM445 (*gyrB*^u *topA*⁺) (Taylor and Menzel, 1995, Gene 167: 69-74) or GP203 (*gyrA*(Nal^r) *topA*⁻) and its
10 companion strain GP202 (*gyrA*(Nal^r) *topA*⁺) ((Pruss et al., 1986, J. Bacteriol. 168 (No. 1): 276-282).

Although such existing strains may be used according to this invention, a carefully constructed set of isogenic strains involving a minimum set of genetic manipulations is
15 desired so as to reduce strain differences to only those genes under consideration. Novel sets of isogenic strains can be constructed in accordance with this invention as described in Section 6.1 and Table I, *infra* and as depicted in FIG. 2. Novel strains for use in the Topo I screen of
20 this invention include *topA*-wild type strain SAD15 and its isogenic *topA*-deleted companion strain SAD16; *topA*-wild type strain RFM431 and its isogenic *topA*-deleted companion strain SAD17; and *topA*-wild type strain SAD19 and its isogenic *topA*-deleted companion strain SAD18 (see FIG. 4A and Table I,
25 *infra*). See also, Table II, in Section 6.2 *infra*, which lists pairs of isogenic test strains that can be used in the Topo I and Type II poison screens of this invention.

According to this embodiment of the invention, a test compound is contacted to the test strains and the
30 differential sensitivity of the strains relative to each other is measured. A test compound that acts by trapping the cleavable complex intermediate of the Topo I enzyme will only inhibit or kill a strain that possesses the target enzyme, but will have no effect on a strain that is lacking Topo I.
35 Thus, a test compound that demonstrates a differential (i.e., increased) DNA damage, growth inhibition and/or killing of the wild type bacterial strain relative to the *topA* mutant

strain is identified as a Topo I poison. See Figure 4A for a depiction of this screening embodiment of the invention.

In another embodiment of the invention, a single bacterial test strain contains a *topA* deletion and therefore lacks the Topo I target enzyme, but it additionally contains a second DNA sequence encoding a functional *topA* gene under the regulatory control of an inducible promoter for the regulated production of Topo I. For example, the strain can contain a second DNA sequence inserted into its bacterial DNA or it can contain a plasmid or other extrachromosomal DNA sequence that carries a functional bacterial *topA* gene operably linked to an inducible promoter. Examples of inducible promoters that can be used for the regulated expression of Topo I according to this invention include the *tac* promoter, the *lac* promoter and *ara*- and *tet*-based systems (see, e.g., Lutz and Bujard, March 1997, Nucl. Acids. Res. 25: 1203-1210). Figures 3A and 3B represent schematic depictions of plasmids that can be used according to this embodiment of the invention for the inducible expression of bacterial Topo I. The recombinant techniques for producing the plasmids utilized according to this embodiment of the invention are well known to those of skill in the art. See, e.g., Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, NY; and Ausubel et al., 1989-1997, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, NY, both of which are incorporated herein by reference in their entirety. For details of the construction of the pECOTOP and pSTPTOP plasmids depicted in Figures 3A and 3B, see Section 6.1, infra. Novel test strains containing inducible *topA* genes that can be used according to this embodiment of the invention include SAD22 and SAD23, which strains can be constructed as described infra in Section 6.1.

Thus, according to this embodiment, the bacterial strain is studied under two different conditions; it is either induced to express Topo I or it is not (see FIG. 4B). The regulated expression of the *topA* gene according to this

embodiment provides the ability, in a single strain, to examine conditions of no or low expression versus conditions of high level expression. Since the general viability of *topA*⁻ strains (without compensatory mutations) is weak, it is preferred to carry out this screen using low versus high induction conditions. In a preferred embodiment of the invention, basal (non-induced) Topo I levels are less than 10% of wild type levels (as assayed by Western analysis) and induction produces a greater than 5-fold increase over basal levels (as assayed by Western analysis). Higher level expression of the *topA* gene results in an increased sensitivity to a Topo I poison since the poison converts the target into a toxic agent. Thus, as with the Topo I poison screen discussed supra, a test compound that causes an increased sensitivity, i.e., DNA damage, growth inhibition and/or killing of the bacterial strain, when induced to produce Topo I relative to the non- or low-induced condition is identified as a Topo I poison.

Additionally, this embodiment of the invention provides a drug screening assay that can be set up to evaluate levels of Topo I expression in excess of those that would be tolerated under normal conditions. According to one embodiment, a *topA*-deleted test strain containing a plasmid bearing the *topA* gene can be induced to produce higher than normal levels of Topo I. That strain can then be compared with an otherwise isogenic strain that is wild type for *topA* and the differential sensitivity to test compounds determined. Alternatively, isogenic *topA*⁺ strains with inducible *topA* genes such as SAD20 or SAD21 (which can be constructed as described infra in Section 6.1) can be used to compare induced versus uninduced conditions. For example, SAD20 could be induced to produce higher than normal levels of Topo I and compared to an SAD20 culture that is uninduced and produces wild-type levels of Topo I.

According to another embodiment of the invention, *E. coli* can be used as the host for the expression of *topA* gene products from other bacteria such as *S. aureus* (see FIG. 3B

and Section 6.1, infra). The *topA* gene from other pathogens such as Salmonella typhimurium, S. fecalis, P. aeruginosa, M. tuberculosis, and H. pylori could also be used. The use of a pathogen-specific target, e.g., Topo I of S. aureus, in the
5 screens of this invention may be desirable in cases where pathogen-specific antibacterial agents are sought.

In any of the screens of this invention as described above, it is preferable to confirm that the Topo I poison identified by the screen causes DNA damage within the
10 bacterial cell. As noted supra and as exemplified infra in Section 6.4 and 6.5, such confirmation can be achieved using techniques known in the art such as DNA damage assays and/or DNA cleavage assays.

15 5.2. METHODS AND COMPOSITIONS FOR
 SCREENING FOR BACTERIAL TYPE II POISONS

As noted supra, in *topA*⁻ bacterial strains, the loss of *topA* function can be compensated for in different ways. A reduction in the level of the bacterial Type II topoisomerase
20 enzyme, DNA gyrase, which aids in supercoiling of the DNA, can compensate for the loss of the DNA relaxing activity of Topo I, while, alternatively, an increase in the levels of Topo IV, which possesses its own DNA relaxing activity, can compensate for the loss of the Topo I relaxing activity.

25 These two distinct mechanisms of compensating for the loss of Topo I have very different consequences with respect to the number of Type II topoisomerase targets in the bacterial cell. *TopA*⁻ strains that compensate for the *topA* defect via reduced gyrase levels will have reduced levels of
30 Type II topoisomerase targets (reduced gyrase plus normal Topo IV), while *topA*-deleted strains that compensate for the *topA* defect via increased Topo IV levels will have increased Type II topoisomerase targets (normal gyrase plus elevated Topo IV). The cells with increased levels of Type II
35 topoisomerase targets will therefore display an increased sensitivity to Type II topoisomerase poisons that trap the cleavable complex intermediates of the target enzymes. The

strategy of varying the levels of the target for the desired antibacterial compound, wherein increased target levels translates into increased sensitivity to the antibacterial compound, parallels the approach described above with respect to the Topo I poisons.

Thus, according to the present invention, bacterial screens are provided for identifying Type II poisons, i.e., those compounds that trap the cleavable complex intermediate of the bacterial Type II DNA topoisomerases. According to a preferred embodiment of the invention, bacterial assays are performed comprising contacting a test compound to bacterial test strains that are isogenic except for the fact that one of the strains has a reduced level of bacterial Type II DNA gyrase targets, while the second strain has an increased level of Type II Topo IV targets. According to a preferred embodiment, one strain has a reduced level of the gyrase enzyme while the other strain has an increased level of the Topo IV enzyme. Since this screen is for the detection of Type II topoisomerase poisons, the isogenic strains used can be either *topA*⁻ or *topA*⁺ as long as they are isogenic for the *topA* gene. As noted above, the strain with reduced levels of the gyrase enzyme will possess a decreased number of targets for a Type II-specific poison whereas the strain with increased levels of Topo IV will possess an increased level of targets for a Type II-specific poison. The strains are contacted with a test compound and the differential sensitivity of the cells are measured. A test compound that causes an increased DNA damage, growth inhibition and/or killing of the strain with the elevated level of Type II DNA topoisomerase, relative to the strain having reduced levels of Type II targets, indicates that the test compound works in concert with the Type II topoisomerase enzymes to poison the cell and hence is identified as an antibacterial Type II DNA topoisomerase poison.

For example, according to a preferred embodiment of the invention, *topA*-deleted test strain A contains a compensatory mutation in the *gyrA* and/or *gyrB* genes that reduces the level

of DNA gyrase in the cell and *topA*-deleted test strain B contains a compensatory mutation (i.e., a duplication) in the *parC* and/or *parE* genes that increases the levels of Topo IV in the cell. See Figure 2 for an illustration of the genetic events involved in the construction of the isogenic *topA*-deleted strains of this screen. See also Section 6.1 and Table I, *infra*, for a description of the construction of specific novel test strains to be used for this screen, e.g., SAD17 or SAD18 (*gyrB* mutants) versus SAD16 (*parC:E* duplication mutant). See also Table II, in Section 6.2, *infra*, for a list of possible isogenic test strain pairs that can be used in the Type II screens of this invention.

The two strains are exposed to a test compound and the differential sensitivity of the cells to the compound is measured. Exposure of the two strains to a test compound that is a Type II topoisomerase poison that traps the cleavable complex intermediate of both the gyrase and Topo IV Type II topoisomerases will result in a significant differential sensitivity between the two strains since strain A contains Type II target levels below wild type while strain B contains Type II target levels above wild type. See Figure 5 for a schematic depiction of this screen.

As noted *supra*, in an alternative embodiment of this screen, test strains A and B containing a *gyrA* and/or *gyrB* mutation and a *parC* and/or *parE* mutation, respectively, can be *topA*⁺. Such strains can be constructed as described in Section 6.1, *infra*, e.g., RFM431 or SAD19 (*gyrB* mutants) versus SAD15 (*parC:E* duplication mutant).

Because the screens of this embodiment involve two different Type II topoisomerase targets, additional tests can be performed to determine whether the poison is in fact interacting with both targets (as in the case of the quinolone antibiotics) or either target alone. Further characterization of the Type II poison can involve comparing the differential sensitivities displayed by the test strains with the differential sensitivities displayed by those test strains with respect to known antibiotic and other

antibacterial drugs. For example, the quinolone antibiotics are known to be Type II poisons that trap the intermediates of both gyrase and Topo IV; therefore, comparison of the differential sensitivity displayed by the test strains to a
5 test compound according to this invention with the differential sensitivities those same strains display to a known quinolone antibiotic can confirm the discovery of novel compounds with a mechanism of action similar to that of the quinolones. In addition, DNA damage assays and/or DNA
10 cleavage assays for the detection of DNA damage caused by the test compound allows for a further confirmation of the compound as a Type II poison.

In alternative screens for Type II poisons, the sensitivity of strains with reduced gyrase levels or
15 increased Topo IV levels can be separately tested against an isogenic wild type strain. This embodiment of the invention allows for the detection of antibacterial compounds that interact with one or the other of the Type II topoisomerases. Please note that since this screen involves a comparison with
20 a strain that is wild type for the Type II topoisomerases and the test strains must be isogenic and viable, both strains in this embodiment should be topA⁺.

For example, in this embodiment, bacterial strains A and B are isogenic except that strain A contains a mutation in a
25 *gyr* gene which results in reduced gyrase levels within the mutant strain while strain B is wild type for the *gyr* gene. Test compounds are then contacted to the test strains and the differential sensitivity of the strains relative to each other is measured. A test compound that causes a decreased
30 sensitivity on the part of strain A containing a *gyr* mutation relative to the wild type strain B, is identified as a Type II DNA gyrase poison. Novel strains that can be used in this embodiment include RFM431 or SAD19, which are *gyrB* mutants, versus wild type RFM430; see Section 6.1, *infra*, for details
35 of the construction of these strains. Alternatively, bacterial strains A and B can be isogenic except that strain A contains a mutation in a *parC* and/or *parE* gene which

results in increased Topo IV levels within the mutant strain while strain B is wild type for those genes. Test compounds are then contacted to the test strains and the differential sensitivity of the strains relative to each other is
5 measured. A test compound that causes an increased sensitivity on the part of strain A containing a *parC* and/or *parE* mutation relative to the wild type strain B, is identified as a Type II Topo IV poison. Novel strains that can be used in this embodiment include SAD15, which is a
10 *parC:E* duplication mutant versus wild type RFM430 (see Section 6.1 and Table I, infra).

6. EXAMPLE

The subsections below describe specific embodiments of
15 the compositions and assays of this invention and are provided solely for the purpose of illustration; they are not in any way meant to limit the scope of the present invention.

6.1 CONSTRUCTION/DESCRIPTION OF THE BACTERIAL TESTS STRAINS OF THE INVENTION

20 Table I below lists various strains that can be used in accordance with the present invention. The table indicates the relevant genotype of each strain as well as the type of mutation possessed by the strain which is relevant to this
25 invention.

30

35

Table I

5	STRAIN	RELEVANT GENOTYPE	RELEVANT MUTATION
	N99	rpsL galK2	
	N4177	rpsL galK2 gyrB221 gyrB203	gyrB topA+
	GR4413	sulA::Mudlac	
10	RFM430	rpsL galK2 ΔtrpE	
	RFM431	rpsL galK2 ΔtrpE gyrB221 gyrB203	gyrB, topA+
	SAD15	rpsL galK2 ΔtrpE (parC,E- duplication:: Tn10dka	TopoIV, topA+
15	SAD19	rpsL galK2 ΔtrpE gyrB225	gyrB, topA+
	SAD17	rpsL galK2 gyrB221 gyrB203 ΔcysBtopA	gyrB, topA-
20	SAD16	rpsL galK2 parC,E- duplication:: Tn10dka ΔcysBtopA	TopoIV, topA-
	SAD18	rpsL galK2 gyrB225 ΔcysBtopA	gyrB, topA-
25	SAD20	rpsL galK2 ΔtrpE /placP-coli topA	
	SAD21	rpsL galK2 ΔtrpE /placP-StaphA topA	
	SAD22	rpsL galK2 ΔcysBtopA /placP-coli topA	topA- inducible topA
30	SAD23	rpsL galK2 ΔcysBtopA /placP-StaphA topA	topA- inducible topA
	SAD24	sulA::Mudlac /placP-coli topA	

35

More specifically, in order to insure isogenic sets of test strains, all bacterial strains used for the

identification of topoisomerase poisons were constructed in the genetic background defined by strain N99 (also known as W3102, see Bachmann, in *Escherichia coli* and *Salmonella typhimurium: Cellular and Molecular Biology*, 1st ed., Neidhardt (ed.), p. 1201, ASM Press 1987). The *gyrB* temperature-sensitive/coumermycin-resistant allele, *gyrB221(cou^R) gyrB203(Ts)*, was isolated in this genetic background as previously described (Menzel and Gellert, 1983, *Cell* 34: 105-113). To ensure an isogenic derivative, this allele was reintroduced into N99 to produce strain N4177 (genotype: N99 *gyrB221(cou^R) gyrB203(Ts)*), using phage P1 transduction (Silhavy et al., *Experiments with Gene Fusions*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1984) by selecting coumermycin resistance (20 µg/ml) and scoring the co-inheritance of the temperature sensitive phenotype.

Next, to facilitate the introduction of a *topA* defect, a *trpE* deletion was placed in the N99 and N4177 genetic backgrounds by the sequential phage P1-mediated transduction of *pyrB ΔtrpE zci::Tn10* (with phage grown on PLK831) by the selection of tetracycline resistance, followed by the transduction of *Ura⁺ (pyrB⁺)* and the retention of a *Trp⁻ (ΔtrpE)* tetracycline-sensitive strain to produce strains RFM430' and RFM431', respectively. Strains RFM430 and RFM431 have been previously described; see, e.g., Drolet et al., 1995, *Proc. Natl. Acad. Sci. USA* 92: 3526-3530. To create a strain with an alternate *gyrB* allele (*gyrB225*) capable of compensating for the loss of the *topA* gene product, the temperature-sensitive character of RFM431' was transduced with phage P1 grown on DM800 (genotype: *Δ(topA cysB)204 acrA13 gyrB225*); see McEachern and Fisher, 1989, *FEBS Lett* 253: 67-70) to growth at 42°C and co-inheritance of the wild type coumermycin-sensitive character was scored to produce strain SAD19. The *topA* gene was deleted from RFM431' and SAD19' by transduction to *Trp⁺* with phage P1 grown on DM800, resulting in the retention of *Cys⁻ (ΔcysBtopA)* transductants such as

SAD17' and SAD18', respectively. These two strains are topA⁻, gyrB mutants (see Table I above).

Strain SAD17' has the unusual property of being both temperature-sensitive (due to the *gyrB*^{TS} allele) and cold-sensitive (due to the combination of the Δ cysBtopA mutation and the *gyrB*^{TS} allele which fails to compensate for the topA deletion at low temperature, e.g., 25°C). Strain SAD17' was therefore used to select for the transposon-mediated duplication (Anderson and Roth, 1979, Cold Spring Harb. Symp. Quant. Biol. 43, Pt. 2: 1083-1087) of the *parC,E* genes following transposon mutagenesis at 18°C, using the transposon Tn10dkan (Eliot and Roth, 1988, Mol. Gen. Genet. 213 (2-3): 332-338). The duplicated nature of the compensatory mutation was verified by demonstrating the unstable character of kanamycin resistance and the co-segregation of kanamycin resistance with the ability to grow at 30°C. A Tn10dkan transposon from such an isolate was transduced by phage P1 into strain RFM430' to form strain SAD15'. SAD15' was subsequently transduced to Trp⁺ with phage P1 grown on DM800, and a Cys⁻ (Δ cysBtopA) transductant, SAD16', was obtained.

In order to improve the sensitivity of the test strains to the test compounds to be screened, derivatives of the strains described above were made hyperpermeable by introduction of the *imp4312* mutation. To do so, Plvir was grown (Silhavy et al., supra) on BAS1329 (*imp4312 leu::Tn10*, Sampson et al., 1989, supra) and used to transduce strains such as SAD15', 16', 17' and RFM431' to tetracycline resistance. Strains co-inheriting the Imp phenotype were identified as described in Sampson et al., supra. The *imp*-derivatives were the test strains used in the actual screening described below. For the purposes of this disclosure, the *imp*⁺ precursors of these strains are designated herein with a prime symbol (e.g., precursor strain SAD'; actual test strain for screening SAD).

In order to obtain test strains containing an inducible topA gene, strain RFM430 is transformed with plasmids,

PECOTOP or PSTPTOP to form strains, SAD20 and SAD21, respectively. PECOTOP contains a functional E. coli topA gene operably linked to a tac promoter and can be formed as follows: PCR primers, GGTGAATATGGGTAAAGCTC and
5 GCTCTTCCACCAAGTGGC are used to amplify DNA corresponding to the E. coli topA gene from an E. coli genomic library (Clontech, Palo Alto CA) using the Advantage-HF PCR kit (Clontech) according to manufacturer's recommendations. These PCR fragments are then cloned into the pGEM-T vector
10 and transformed into the host strain JM109 (Promega, Madison WI). Fidelity of the product can be verified by DNA sequence analysis according to standard procedures and would be expected to be identical with the published sequence (see, e.g., European patent application EP 0 835 938 A2). To
15 create a regulated expression clone, these sequences are excised from the PGEM clone and used to replace the human Topo I gene that is contained in the plasmid pMStop1 which is described in Taylor and Menzel, 1995, Gene 167: 69-74. Techniques for incorporating the E. coli Topo I sequences
20 from the PGEM clone into PMSTOP1 are standard and commonly practiced by those of ordinary skill in the art (see, e.g., Ausubel et al., 1989-1997, Current Protocols in Molecular Biology, supra). The resultant product is PECOTOP (FIG. 3A), which is transformed into strain RFM430 to create strain
25 SAD20. Strain SAD22 can then be derived from SAD20 by transduction to Trp⁺ and retention of the cys⁻ (Δ cystop) co-transductant using bacteriophage P1 as described above for the creation of SAD17 from RFM431.

Similarly, PSTPTOP, which contains a functional S.
30 aureus topA gene operably linked to a tac promoter, can be constructed as described above using PCT primers, ATGGGCAGCAGCCATCATCA and TTATTTCTGCGCTGCCTCTT for the amplification of DNA corresponding to the gene for S. aureus Topo I from an S. aureus genomic library (Clontech). As
35 above, the PCR fragments can be cloned into the PGEM-T vector and transformed into JM109 and subsequently excised therefrom to replace the human Topo I gene of PMSTOP1. The resultant

PSTPTOP plasmid (FIG. 3B) is transformed into strain RFM430 to create strain SAD21. Strain SAD23 is then constructed from SAD21 by transduction to Trp⁺ and retention of the cys⁻ (Δ cystop) co-transductant using bacteriophage P1 as described above. Strain SAD24 is formed by the transformation of strain GR4413 with PECOTOP.

6.2 DIFFERENTIAL SENSITIVITY ASSAY IN AGAR

The following procedure was used for the identification of bacterial Topo I poisons as well as bacterial Type II topoisomerase poisons. Generally, paired test strains were grown in culture and then transferred to agar plates. If bacterial strains with the imp mutation are used, i.e., to increase permeability to the test compound, the strains should not be kept on agar (either on a plate or on a slant) for more than a day or two. The cultures which were the source of the cells used for screening can be stored either at -80°C or preferably, in 20% glycerol at -20°C. Such a working frozen glycerol stock can be used for up to a year. Small aliquots of the frozen culture were used to inoculate liquid broth prior to each experiment.

As examples of the screens of this invention, a Topo I screen compared strains SAD15 and SAD16, whereas a Type II topoisomerase screen compared SAD16 and SAD17 (see, e.g., Section 6.1 and Table I, supra and Table II, infra). As indicated in Table II, infra, screens similar to those exemplified herein can be readily performed using the paired test strains listed in that Table.

In preparation for the screen, between 50-100 μ l of frozen solid from each "working frozen", i.e., for each one of the paired test strains to be tested, was used to inoculate a 5 ml culture of liquid Luria Broth (LB) containing appropriate antibiotics, and the cultures were grown aerobically overnight at 37°C with gyratory shaking. Strains containing the *parC,E* duplication such as SAD 15 and SAD16 were grown in the presence of 25 mg/ml kanamycin and 12.5 mg/ml tetracycline, whereas strains containing the

gyrase mutation such as SAD17 were cultured in 12.5 mg/ml tetracycline. These overnight cultures were then subcultured 1:40 in LB media without antibiotics 4 to 5 hours prior to final plate preparation and the cell OD at A_{600} was measured.

5 Prior to the assay procedure, plates (bottom agar) were prepared by adding 30 ml of LB media with 1.5% agar in 125 x 84 mm rectangular petri dishes. The plates were allowed to solidify and stored inverted at least 24 hours prior to use to permit drying. For the assay, fresh cells from each test
10 strain prepared as described above were added to liquified top agar (LB + 1.0% low melt agarose at 37°C) such that 0.08 A_{600} OD units of cells were added per ml. The liquid top agar mixture (12 ml per plate) was poured onto the bottom agar and allowed to harden for at least one hour at room temperature
15 prior to application of the test compound.

Test compounds (dissolved in 100% DMSO at a nominal concentration of 2.5 Mm) arrayed in microtiter plates were delivered (1 μ l) to the agar surface using a 96-pin device (VP Scientific, San Diego CA). In the Type II screens,
20 dilutions of the DNA gyrase poison, Norfloxacin, were included in control wells. Plates were inverted and incubated overnight at 37°C.

After 24 hours of incubation, the plates were removed and scored for the presence of clearing zones -- areas where
25 bacterial growth is not apparent against a background lawn of growth. A differential growth inhibition, i.e., a zone of no or reduced growth exhibited by one of the strains of the pair compared to the other (where identical samples of a test compound have been applied) indicates that test compound is a
30 Topo I or Type II topoisomerase poison, depending upon the particular screen performed.

For example, Figure 4A depicts a typical Topo I screen of the invention, wherein an otherwise isogenic test strain pair, i.e., strains that are isogenic except that one strain
35 is *topA*⁻ and the other is *topA*⁺, are exposed to a test compound. A test compound that acts as a general poison will create a zone of growth inhibition on both the *topA*⁻ and *topA*⁺

plates. A test compound that is non-poisonous will create no zone of inhibition on either plate. However, a test compound that is a Topo I poison, i.e., acting through its effect on Topo I targets, can only inhibit the *topA*⁺ test strain which
5 will show a zone of inhibition; since the *topA*-deleted test strain does not contain a Topo I target, it will demonstrate no zone (or a dramatically reduced zone) of inhibition.

In fact, in the specific Topo I poison screen exemplified herein, wild type, *topA*⁺ test strain SAD15 and
10 its isogenic, *topA*⁻ companion strain SAD16 were tested with various test compounds and in numerous instances, a zone differential of growth inhibition was observed, i.e., SAD15 exhibited a zone of inhibition whereas SAD16 did not, or exhibited a very small zone of inhibition. Those test
15 compounds that gave these results were considered Topo I poisons and were arrayed to new plates and retested to confirm activity (see Results Section 6.3, *infra*). As indicated in Figure 4A and in Table II below, similar screens can be run with paired, isogenic strains RFM431/SAD17 and
20 SAD19/SAD18.

In the embodiment of the Topo I screen of the invention wherein the test strain contains an inducible promoter for the expression of the *topA* gene, the test strain containing the inducible gene is treated so as to induce the
25 production of Topo I prior to exposure to the test compound. For example, in this embodiment, 10 cm petri dishes containing 40 ml of LB-agar with 50 µg ampicillin/ml with (+) or without (-) IPTG are overlaid with 10⁸ midlog *topA*-deleted test strain cells in 4 ml of soft (0.7% agar) LB-agar at 48°C.
30 When the soft-agar overlays have solidified, 4 mm cylindrical holes or wells are cored to the bottom of each petri dish using a small probe attached to a vacuum. The test compound is then added to the wells and the zones of inhibition around the wells are measured after 14-18 h of growth at 30°C.

35 For example, as depicted in Figure 4B, either of the *topA*-deleted test strains SAD22 and SAD23, which contain, respectively, the PECOTOP and PSTPTOP plasmids described in

Section 6.1 above and depicted in Figures 3A and 3B, can be grown with or without IPTG (an inducer of *topA* expression through its effect on the *lacI* gene of the plasmid). When the inducer is present, the *topA* gene will be expressed and produce Topo I targets in the form of the Topo I enzyme; without the presence of the inducer, the strain will lack or have reduced Topo I targets.

Application of a test compound to the plates containing the test strain in an induced vs. non-induced or low-induced condition, will indicate whether that test compound is a Topo I poison as follows: A general poison will produce an essentially identical zone of inhibition on both plates, while a compound that is not a poison will demonstrate no zone of inhibition on either plate. However, a Topo I poison will produce a larger zone of growth inhibition on the induced plate than on the non- or low level-induced plate since the induced test strain will contain a greater number of Topo I targets for interaction with the poison than the non- or low-induced strain.

Similarly, test strains SAD20 and 21, which contain the PECOTOP and PSTPTOP plasmids, respectively, can be used in this inducible Topo I screen wherein either strain can be grown in the presence of IPTG for high level expression of Topo I and compared with the strain in an uninduced condition, i.e., having a wild type level of Topo I expression. A differential zone of growth inhibition displayed by the test pair upon exposure to a test compound indicates that the test compound is a Topo I poison.

As to the Type II topoisomerase poison screen of the invention, the procedure was the same as described above utilizing the appropriate isogenic test strains, e.g., one strain that contained a reduced level of Type II topoisomerase targets and the other strain that contained an elevated level of such targets. According to a preferred embodiment, isogenic strains, one of which contains a mutation in the *gyrA* and/or *gyrB* genes and one of which contains a duplication of the *parC* and/or *parE* genes, were

utilized. As indicated in Figure 5, according to this screen, a test compound that is a Type II topoisomerase poison will create a larger zone of growth inhibition on the plate containing the strain having the greater level of Type II targets for the poison. As noted above, strains SAD16 and SAD17 were tested using this screen. Numerous test compounds gave a differential zone of growth inhibition in this screen, i.e., SAD16 exhibited a greater zone of inhibition than SAD17. See, e.g., Section 6.3, *infra* for results. As indicated in Figure 5, other isogenic test strain pairs that can be used in this Type II screen include RFM431 and SAD15, SAD19 and SAD15, and SAD18 and SAD16. In addition, test strain pairs RFM431/RFM430, SAD19/RFM430 or SAD15/RFM430 could also be used.

Table II below sets forth various pairs of isogenic strains that can be used in the Topo I or Type II poison screens of this invention.

Table II

Pairs of Isogenic Strains
For Use In The Screens Of The Invention

TOPO I POISON SCREENS	TYPE II POISON SCREENS
SAD15/SAD16	RFM431/SAD15
RFM431/SAD17	SAD19/SAD15
SAD19/SAD18	SAD17/SAD16
SAD22 INDUCED/NON-INDUCED	SAD18/SAD16
SAD23 INDUCED/NON-INDUCED	RFM431/RFM430
SAD20 INDUCED/NON-INDUCED	SAD19/RFM430
SAD21 INDUCED/NON-INDUCED	SAD15/RFM430

6.3. TEST COMPOUND RESULTS OF SCREENS

Using the Topo I screen exemplified above, 19 test compounds were scored as Topo I poisons and six have been confirmed as such to date, using the DNA damage assay and the DNA cleavage assay described in Sections 6.4 and 6.5, infra, respectively. These poisons have also been shown to inhibit relaxation by bacterial Topo I in an inhibition assay described by Tse-Dinh, Y-C. et al., 1988, J. Biol. Chem. 263: 5560-5565 and to have cleaved DNA in the presence of bacterial Topo I enzyme using techniques as described in Tse-Dinh, Y-C., 1986, J. Biol. Chem. 261: 10931-10935 and Zhu et al., 1998, J. Biol. Chem. 273: 8783-8789.

Using the Type II poison screen exemplified above, 56 test compounds were scored as Type II poisons and of these, seven have been confirmed to date, using the DNA damage and DNA cleavage assays described infra. These compounds have also been shown to inhibit DNA gyrase using techniques as described by Reece and Maxwell, 1989, J. Biol. Chem. 266: 3540-3546. Two of these poisons are quinolones, an expected compound class as discussed supra, thus confirming the screening procedure. Five of the seven confirmed poisons represent novel structures not previously reported to have Type II inhibitory activity.

In addition, because quinolones were known to be Type II poisons, known quinolones were run as controls in the Type II screen of the invention to verify its validity. Furthermore, Table III below shows the results of a Type II poison screen of the invention using two quinolone compounds, which are known to be Type II topoisomerase poisons.

30

35

Table III

5	Compound	Zone Size	
		SAD16 (elevated type II Topo)	SAD17 (reduced type II Topo)
	Norfloxacin (50 ug/ml)	10 mm	7.0 mm
	Ciprofloxacin (10 ug/ml)	11.5 mm	8.0 mm
10	Ampicillin (1.25 mg/ml)	8.0 mm	9.5 mm
	Echinomycin (0.25 mg/ml)	8.0 mm	8.0 mm

This table indicates the behavior of the type II
 15 topoisomerase test strains SAD16 and SAD17 with two known
 type II poisons (norfloxacin and ciprofloxacin) and two
 control antibacterial compounds. The assay was performed as
 described in Section 6.2, supra. The zone size is the
 measured diameter of the area around the well where bacterial
 20 growth was inhibited. As can be seen, the two quinolones
 created a larger zone of growth inhibition on SAD16 than on
 SAD17, a result indicative of a Type II poison (whereas the
 expected differential sensitivity was not observed with the
 control antibacterial compounds). This control experiment
 25 indicates that the Type II screen of the invention operates
 as disclosed herein.

6.4 DNA DAMAGE ASSAY

As noted herein, it may be desirable to confirm the DNA-
 30 damaging effect of the Topo I or Type II poisons identified
 by the screens of this invention. An example of one such
 confirmatory test is a DNA damage assay wherein the ability
 of a test compound to cause DNA damage can be assessed by
 measuring β -galactosidase activity in a culture of E.coli
 35 cells containing a DIN (DNA damage inducible) promoter fused
 to β -galactosidase (Huisman, O. et al., supra; and Kenyon C.
 et al., 1982, J. Mol. Biol. 160: 445-457) following the

exposure of such a culture to the compound in question. For example, in a liquid culture format, strain GR4413 (Huisman et al., supra), which contains the *suIA-lac* regulatory sequence, was used an inoculum (1:100 from a culture with an A650 value = 0.6 OD units) for fresh Luria broth liquid. 190 μ l aliquots were added to duplicate 10 μ l samples of test compound (in 100% DMSO) distributed into the wells of a flat bottom polystyrene microtiter plate. The microtiter plate was incubated overnight (12-16 hours) at 30°C without shaking. These cultures in microtiter format were then assayed for β -galactosidase activity as described by Menzel, R., 1989, Anal. Biochem. 181: 40-50. Following this growth and test compound exposure, final cell A650 values were determined using a microtiter reader. These cells were then made permeable by transferring separate 150 μ l cultures from each well of the incubation plate to 30 μ l of CHCl₃ present in the corresponding well of a polypropylene microtiter plate using an automated pipetting device. The cultures were made permeable by repeated pipetting up and down (in place; 10X). At this time, a β -galactosidase assay was initiated by using an automated pipetting device to carefully (so as to not disturb the CHCl₃ in the bottom of the microtiter plate well) transfer 20 μ l of the CHCl₃-treated culture to 180 μ l of prewarmed (28°C) Z-buffer (60 mM Na₂HPO₄, 40 mM NaH₂PO₄, 10 mM KCl, 1 mM MgSO₄, and 50 mM β -mercaptoethanol) with 1 mg/ml chlorophenol-red β -D-galactopyranoside (CPRG) present in each of the wells of a clear flat bottom polystyrene microtiter plate. The assay's progress was monitored by immediately transferring the plate to a microtiter reader (with a 28°C temperature controlled chamber) and following the change in A595 (Eustice, D.C. et al., 1991, BioTechniques 11: 739-742). Final β -galactosidase specific activities (normalized to a cell A650 of 1.0 to adjust for differences in growth) were calculated from a kinetic assay as described by Menzel, 1989, supra. Compounds causing significant increases in β -galactosidase activity (>2X) were judged to be active in this DNA damage assay.

Alternatively, the ability of compounds to cause DNA damage was assessed in an agar plate format. To perform this assay, 400 ml of Luria broth with 1.5% agar was sterilized and allowed it to cool to 50°C, followed by the addition of 10 ml of an inoculum culture (GR4413 A650 value = 0.6 OD units) and 3.2 ml of a 50 mg/ml 5-bromo-4-chloro-3-phenol-indolyl- β -D-galactopyranoside(X-gal) in dimethylformamide. 40 ml aliquots of this mixture were poured into 125 x 84 mm rectangular petri dishes and the agar was allowed to solidify. Compounds to be tested were applied to the surface of the agar in aliquots of 1-2 μ l using commercially available 96 prong applicator devices (VP Scientific; San Diego, CA). For larger volumes (3-20 μ l), wells may be cored into the agar and then filled with the test compound. In all cases, responses must be compared to solvent controls. Any material showing a response (a zone of hydrolyzed blue X-gal) stronger than the solvent control alone was considered positive, i.e., a DNA damage signal.

20

6.5 DNA CLEAVAGE ASSAY

To perform the cleavage assay, a plasmid substrate, such as pBR322, was cut with a restriction endonuclease (e.g., EcoR1) to convert the substrate into a linear form. This linear substrate was radioactively end-labeled employing standard methods well known to those practiced in the art (see Ausubel, supra or Chen et al., 1984, Proc. Natl. Acad. Sci. 259: 13560-13566). The actual cleavage reaction (20 μ l) was performed by mixing the test compound, the end-labeled DNA fragment (50 ng) and the appropriate purified topoisomerase enzyme, e.g., either E. coli DNA gyrase (Reece and Maxwell, supra), topoisomerase IV (Peng and Marians, 1993, J. Biol. Chem. 268: 24481-24481), E. coli topoisomerase I (Tse-Dinh, Y-C. et al., 1988, J. Biol. Chem. 263: 5560-5565) or human topoisomerase II (as a control) (Chen et al., supra) in their appropriate respective buffers at 37°C. The cleavage reaction was terminated after 30 minutes through denaturing the topoisomerases by making reaction buffer 0.5%

SDS. Subsequent to this protein denaturation step, DNA was freed from the topoisomerase-DNA cleavage product by protease treatment (1 μ l of 1.5 mg/ml proteinase K per 20 μ l, 1 hour at 42°C). The samples were then deproteinized with CHCl₃-
5 phenol as described by Ausubel, supra, and electrophoresis was used to resolved the end-labeled cleavage products on either agarose gels (1%, low resolution) or acrylamide gels (8%, 29:1 acrylamide to bis, for high resolution) according to standard procedures. Following electrophoretic
10 resolution, visualization of the products was accomplished by autoradiography. Cleavage was indicated by the appearance of discrete low molecular weight species.

15

20

25

30

35

WHAT IS CLAIMED:

1. A method for screening for antibacterial compounds that interact with bacterial DNA topoisomerases comprising:
 - 5 (a) providing at least one pair of bacterial test strains that are isogenic except that the strains vary in their levels of bacterial DNA topoisomerase targets;
 - (b) contacting a test compound to the test strains; and
 - (c) detecting a differential sensitivity between the
- 10 strains to the test compound.
2. The method of claim 1 wherein the bacterial test strains vary in the levels of bacterial DNA Topoisomerase I targets.
- 15 3. The method of claim 1 wherein the bacterial test strains vary in the levels of bacterial DNA topoisomerase Type II targets.
4. The method of claim 1 wherein the bacterial test strains
- 20 vary in enzyme levels of bacterial DNA Topoisomerase I.
5. The method of claim 1 wherein the bacterial test strains vary in enzyme levels of bacterial topoisomerase Type II.
- 25 6. The method of claim 1 wherein the test compound is a DNA Topoisomerase I poison.
7. The method of claim 1 wherein the test compound is a DNA topoisomerase Type II poison.
- 30 8. The method of claim 1 wherein the differential sensitivity of the strains is detected by measuring DNA damage to the bacterial strains after exposure to the test compound.
- 35

9. The method of claim 8 wherein DNA damage is measured by assays which measure cell death or assays which measure growth inhibition.
- 5 10. The method of claim 8 wherein the DNA damage is measured by DNA damage assays or DNA cleavage assays.
11. A method for screening for antibacterial compounds that interact with bacterial DNA Topoisomerase I comprising:
- 10 (a) providing at least one pair of bacterial test strains that are isogenic except that one of the strains contains a *topA* mutation that results in a reduced level of DNA Topoisomerase I targets within said test strain relative to the other strain;
- 15 (b) contacting a test compound to the test strains; and
(c) detecting a differential sensitivity between the test strains to the test compound.
12. The method of claim 11 wherein the *topA* mutation is a
20 *topA* deletion mutation.
13. The method of claim 11 or 12 wherein the strains additionally contain a second site mutation that compensates for the *topA* mutation in one of the strains.
- 25 14. The method of claim 13 wherein the compensatory second site mutation is selected from the group consisting of the *gyrA* gene, the *gyrB* gene, the *parC* gene, the *parE* gene, a combination of the *gyrA* and *gyrB* genes, and a combination of
30 the *parC* and *parE* genes.
15. The method of claim 13 wherein the isogenic test strain pair is selected from the group consisting of SAD15 and SAD16, RFM431 and SAD17, and SAD19 and SAD18.
- 35 16. The method of claim 11 wherein the differential sensitivity of the strains is detected by measuring DNA

damage to the bacterial strains after exposure to the test compound.

17. The method of claim 16 wherein DNA damage is measured by
5 assays which measure cell death or assays which measure growth inhibition.

18. The method of claim 16 wherein the DNA damage is measured by DNA damage assays or DNA cleavage assays.

10

19. A method for screening for antibacterial compounds that interact with bacterial DNA Topoisomerase I comprising:

(a) providing at least two separate cultures of a bacterial test strain that contains a *topA* mutation that
15 results in a reduced level of DNA Topoisomerase I targets within the test strain, which strain additionally contains a functional *topA* gene operably linked to an inducible promoter;

(b) growing the first culture of the strain under
20 conditions in which the strain is induced to produce DNA Topoisomerase I;

(c) separately growing the second culture of the strain under conditions of either no induction or a low-level induction compared to the induction of step (b);

25 (d) contacting a test compound to the cultures grown according to (b) and (c); and

(e) detecting a differential sensitivity to the test compound between the cultures grown under the different conditions.

30

20. The method of claim 19 wherein the mutation is a *topA* deletion mutation.

21. The method of claim 19 or 20 wherein the functional *topA*
35 gene operably linked to an inducible promoter is carried on a plasmid within the bacterial strain.

22. The method of claim 21 wherein the plasmid is PECOTOP or PSTPTOP.
23. The method of claim 19 wherein the functional topA gene
5 operably linked to an inducible promoter is inserted into the bacterial DNA.
24. The method of claim 19 or 20 wherein the inducible promoter is selected from the group consisting of the tac
10 promoter, the lac promoter, ara-based promoters and tet-based promoters.
25. The method of claim 21 wherein the inducible promoter is selected from the group consisting of the tac promoter, the
15 lac promoter, ara-based promoters and tet-based promoters.
26. The method of claim 19 or 20 wherein the strain further contains a compensatory second site mutation.
- 20 27. The method of claim 21 wherein the strain further contains a compensatory second site mutation.
28. The method of claim 26 wherein the compensatory second site mutation is selected from the group consisting of the
25 *gyrA* gene, the *gyrB* gene, the *parC* gene, the *parE* gene, a combination of the *gyrA* and *gyrB* genes, and a combination of the *parC* and *parE* genes.
29. The method of claim 27 wherein the compensatory second
30 site mutation is selected from the group consisting of the *gyrA* gene, the *gyrB* gene, the *parC* gene, the *parE* gene, a combination of the *gyrA* and *gyrB* genes, and a combination of the *parC* and *parE* genes.
- 35 30. The method of claim 19 wherein the bacterial test strain is selected from the group consisting of SAD22, SAD23, SAD20, and SAD21.

31. The method of claim 19 wherein the differential sensitivity is detected by measuring DNA damage to the bacterial strains after exposure to the test compound.

5

32. The method of claim 31 wherein DNA damage is measured by assays which measure cell death or assays which measure growth inhibition.

10 33. The method of claim 31 wherein the DNA damage is measured by DNA damage assays or DNA cleavage assays.

34. The method of claim 19 wherein the bacterial strain is an *E. coli* strain and the functional *topA* gene is derived
15 from a different bacterium selected from the group consisting of *S. typhimurium*, *S. aureus*, *S. fecalis*, *P. aeruginosa*, *M. tuberculosis* and *H. pylori*.

35. A method for screening for antibacterial compounds that
20 interact with bacterial Type II DNA topoisomerases comprising:

- (a) providing at least one pair of bacterial test strains that are isogenic except that one of the strains has a reduced level of bacterial Type II topoisomerase targets
25 relative to the other strain;
- (b) contacting a test compound to the test strains; and
- (c) detecting a differential sensitivity between the test strains to the test compound.

30 36. A method for screening for antibacterial compounds that interact with bacterial Type II DNA topoisomerases comprising:

- (a) providing at least one pair of bacterial test strains that are isogenic except that one of the strains has
35 a reduced level of bacterial Type II DNA gyrase targets and the other strain has an increased level of Type II Topoisomerase IV targets;

- (b) contacting a test compound to the test strains;
- (c) detecting a differential sensitivity between the test strains to the test compound; and
- (d) identifying the test compound as an antibacterial compound.

37. The method of claim 36 wherein the strain with a reduced level of DNA gyrase targets contains a mutation in the *gyrA* or *gyrB* gene or a combination of said genes and the strain with an increased level of Type II Topoisomerase IV contains a mutation in the *parC* or *parE* genes or a combination of said genes.

38. The method of claim 37 wherein the mutation in the *parC* or *parE* gene or a combination of said genes is a duplication.

39. The method of claim 37 wherein the isogenic test strain pair is selected from the group consisting of RFM431 and SAD15, SAD19 and SAD15, SAD17 and SAD16, and SAD18 and SAD16.

40. The method of claim 36 further comprising comparing the differential sensitivity displayed by the test strain pair to the test compound with the differential sensitivity displayed by the same test strain pair to other known antibacterial compounds.

41. A method for screening for antibacterial poisons that interact with bacterial Type II DNA gyrase comprising:

- (a) providing at least one pair of bacterial test strains that are isogenic except that one of the strains has a mutation in a *gyr* gene which results in a reduced level of bacterial Type II DNA gyrase within the strain and the other strain is wild type for the *gyr* gene;
- (b) contacting a test compound to the test strains; and
- (c) detecting a differential sensitivity between the test strains to the test compound.

42. A method for screening for antibacterial poisons that interact with bacterial Type II DNA Topoisomerase IV comprising:

- (a) providing at least one pair of bacterial test
5 strains that are isogenic except that one of the strains has a mutation in a *par* gene which results in an increased level of bacterial Type II DNA Topoisomerase within the strain and the other strain is wild type for the *par* gene;
(b) contacting a test compound to the test strains; and
10 (c) detecting a differential sensitivity between the test strains to the test compound.

43. The method of claim 42 wherein the mutation in the *par* gene is a duplication.

15

44. The method of claims 35, 36, 41 or 42 wherein the differential sensitivity is detected by measuring DNA damage to the bacterial strains after exposure to the test compound.

20 45. The method of claim 44 wherein DNA damage is measured by assays which measure cell death or assays which measure growth inhibition.

46. The method of claim 44 wherein the DNA damage is
25 measured by DNA damage assays or DNA cleavage assays.

30

35

1/6

FIG. 1A




FIG. 1B





FIG. 1C



2/6




FIG.2




FIG.3A




FIG.3B

pSTPTOP

SUBSTITUTE SHEET (RULE 26)




FIG.4A




FIG.4B




FIG.5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/23384

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/04, 1/06, 1/18

US CL :435/4, 29, 32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/4, 29, 32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS; DIALOG DATABASES: BIOSIS PREVIEWS, CA SEARCH, WORLD PATENT INDEX, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FLAMM, R. K. et al. In Vitro Evaluation of ABT-719, a Novel DNA Gyrase Inhibitor. Antimicrobial Agents and Chemotherapy. April 1995, Vol. 39, No. 4, pages 964-970, see entire document.	1-46
A	NAKANE, T. et al. In Vitro Antibacterial Activity of DU-6859a, a New Fluoroquinolone. Antimicrobial Agents and Chemotherapy. December 1995, Vol. 39, No. 12, pages 2822-2826, see entire article.	1-46

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 FEBRUARY 1999

Date of mailing of the international search report

09 FEB 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHNNY F. RAILEY II, PH.D.

Telephone No. (703) 308-0196